[1]
|
López-Munoz, F., Alamo, C., Cuenca, E., Shen, W.W., Clervoy, P. and Rubio, G. (2005) History of the discovery and clinical introduction of chlorpromazine. Annals of Clinical Psychiatry, 17, 113-135.
doi:10.1080/10401230591002002
|
[2]
|
Shen, W.W. (1999) A history of antipsychotic drug development. Comprehensive Psychiatry, 40, 407-414.
doi:10.1016/S0010-440X(99)90082-2
|
[3]
|
Kane, J., Honigfeld, G., Singer, J. and Meltzer, H. (1988) Clozapine for the treatment-resistant schizophrenic. Archives of General Psychiatry, 45, 780-796.
|
[4]
|
Hippius, H. (1999) A historical perspective of clozapine. Journal of Clinical Psychiatry, 60, 22-23.
|
[5]
|
López-Munoz, F. and álamo, C. (2011) Neurobiological background for the development of new drugs in schizophrenia. Clinical Neuropharmacology, 34, 111-126.
doi:10.1097/WNF.0b013e318215c2f7
|
[6]
|
Shinfuku, N. (2012) What are happening in the mental health system in Japan: Some observations. Taiwanese Journal of Psychiatry, 26, 70-76.
|
[7]
|
López-Munoz, F., Vieta, E., Rubio, G., García-García, P. and Alamo, C. (2006) Bipolar disorder as an emerging pathology in the scientific literature: A bibliometric approach. Journal of Affective Disorders, 92, 161-170.
doi:10.1016/j.jad.2006.02.006
|
[8]
|
López-Munoz, F., álamo, C., Quintero-Gutiérrez, F.J. and García-García, P. (2008) A bibliometric study of international scientific productivity in attention-deficit hyperactivity disorder covering the period 1980-2005. European Child and Adolescent Psychiatry, 17, 381-391.
doi:10.1007/s00787-008-0680-1
|
[9]
|
López-Munoz, F., García-García, P., Sáiz-Ruiz, J., Mezzich, J.E., Rubio, G., Vieta, E. and álamo, C. (2008) A bibliometric study of the use of the classification and diagnostic systems in psychiatry over the last 25 years. Psychopathology, 41, 214-225. doi:10.1159/000125555
|
[10]
|
López-Munoz, F., Alamo, C., Rubio, G., García-García, P., Martín-Agueda, B. and Cuenca, E. (2003) Bibliometric analysis of biomedical publications on SSRIs during the period 1980-2000. Depression & Anxiety, 18, 95-103. doi:10.1002/da.10121
|
[11]
|
López-Munoz, F., Shen, W.W., Moreno, R., Molina, J.D., Noriega, C., Pérez-Nieto, M.A., Rubio, G. and álamo, C. (2012) International scientific productivity on secondgeneration antipsychotic drugs in Taiwan: A bibliometric study. Taiwanese Journal of Psychiatry, 26, 114-129.
|
[12]
|
Price, D.J.S. (1963) Little science, big science. Columbia University Press, New York.
|
[13]
|
Bradford, S.C. (1948) Documentation. Crosby Lockwood, London.
|
[14]
|
OECD Health Division (2011) OECD Health Data 2011 —Frequently Requested Data. OECD, Paris.
|
[15]
|
World Health Organisation Department of Health Statistics and Informatics (2011) World Health Statistics 2011. WHO, Geneva.
|
[16]
|
Shen, W.W. (2011) Clinical Psychopharmacology for the 21 Century, the Third Edition (in Mandarin). Ho-Chi Publishing Company, Taipei.
|
[17]
|
Clement, S., Singh, S., and Burns, T. (2003) Status of bipolar disorder research. British Journal of Psychiatry, 182, 148-152. doi:10.1192/bjp.182.2.148
|
[18]
|
Theander, S.S. and Wetterberg, L. (2010) Schizophrenia in Medline 1950-2006: A bibliometric investigation. Schizophrenia Research, 118, 279-284.
doi:10.1016/j.schres.2009.05.013
|
[19]
|
Shen, W.W., López-Munoz, F. and Alamo, C. (2006) Acido valproico y carbamazepina en el tratamiento del trastorno bipolar: Desarrollo histórico. In: López-Munoz, F. and álamo, C., Eds., Historia de la Psicofarmacología, Médica Panamericana, Madrid, 2, 771-782.
|
[20]
|
Takezaki, H. and Hanaoka, M. (1971) The use of carbamazepine (Tegretol) in the controlod manic-depressive psychosis and other manic, depressive states. Seishin Igaku (Folia Psychiatry Neurology) (in Japanese), 13, 173-182.
|
[21]
|
Hirai, Y., Yamanaka, Y., Kusama, M., Ishibashi, T., Sugiyama, Y. and Ono, S. (2012) Analysis of the success rates of new drug development in Japan and the lag behind the US. Health Policy, 104, 241-246.
doi:10.1016/j.healthpol.2011.11.008
|
[22]
|
Shimazawa, R. and Ikeda, M. (2011) Delays in neurological drug development in Japan. Internal Medicine, 50, 1565-1568. doi:10.2169/internalmedicine.50.5061
|
[23]
|
Shimazawa, R., Kusumi, I. and Ikeda, M. (2012) Delays in psychiatric drug development in Japan. Journal of Clinical Pharmacy and Therapeutics, 37, 348-351.
doi:10.1111/j.1365-2710.2011.01311.x
|
[24]
|
Tajima, O. (2001) Mental health care in Japan: Recognition and treatment of depression and anxiety disorders. Journal of Clinical Psychiatry, 62, 44.
|
[25]
|
Sim, K., Su, A., Fujii, S., Chong, M.Y., Ungvari, G.S., Si, T., Chung, E.K., Tsang, H.Y., Chan, Y. H., Heckers, S., Shinfuku, N. and Tan, C.H. (2004) Antipsychotic polypharmacy in patients with schizophrenia: A multicentre comparative study in East Asia. British Journal of Clinical Pharmacology, 58, 178-183.
doi:10.1111/j.1365-2125.2004.02102.x
|
[26]
|
Sim, K., Chuan, H., Fujii, S., Yang, S.I., Chong, M.Y., Ungvari, G.S., Si, T., He, Y.L., Chung, E.K., Chan, Y.H., Shinfuku, N., Kua, E.H., Tan, C.H. and Sartorius, N. (2009) High-dose antipsychotic use in schizophrenia: A comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. British Journal of Clinical Pharmacology, 67, 110-117.
doi:10.1111/j.1365-2125.2008.03304.x
|